CLINICAL_TRIALS
trial_result
· 2018-06-06
Clinical Trial Update: Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Summary
A post-marketing surveillance study of sorafenib (Nexavar) for renal cell carcinoma in Japan has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Status: COMPLETED